<p>Akebia Therapeutics（納斯達克股票代碼：AKBA - 獲取免費報告）預計將在 2025 年第二季度的季度財報發佈之前，於 8 月 7 日星期四市場開盤前發佈。分析師預計該公司將宣佈每股收益為（$0.02），季度收入為 4760 萬美元。</p>
<ul>
<li>Akebia Therapeutics 因 FDA 批准貧血治療而大幅上漲</li>
</ul>
<p>Akebia Therapeutics（納斯達克股票代碼：AKBA - 獲取免費報告）最近一次發佈季度財報是在 5 月 8 日星期四。這家生物製藥公司報告該季度每股收益為$0.03，超出分析師一致預期的（$0.03）$0.06。該公司在該季度的收入為 5734 萬美元，而分析師預期為 4488 萬美元。分析師平均預計 Akebia Therapeutics 在當前財政年度的每股收益為$0，下一財政年度的每股收益也為$0。</p>
<p>獲取 <strong>Akebia Therapeutics</strong> 的提醒：</p>
<h2>Akebia Therapeutics 股價上漲 0.8%</h2>
<p>在週五的午盤交易中，納斯達克 AKBA 的股票上漲了$0.03，達到了$3.72。該股票的交易量為 3,017,137 股，而其平均交易量為 4,131,279 股。該公司的市值為 9.7702 億美元，市盈率為-17.71，貝塔值為 0.88。Akebia Therapeutics 的 12 個月低點為$1.07，12 個月高點為$4.08。該公司的債務與股本比率為 1.89，速動比率為 2.02，流動比率為 2.23。該公司的 50 日移動平均價格為$3.61，200 日移動平均價格為$2.64。</p>
<h2>Akebia Therapeutics 的內部交易</h2>
<p>在相關消息中，首席財務官 Erik Ostrowski 於 6 月 30 日星期一出售了 41,314 股公司的股票，交易價格為每股平均$3.67，總價值為$151,622.38。交易後，首席財務官持有 503,586 股公司股票，價值約為$1,848,160.62。此次交易代表其持股比例下降了 7.58%。該出售在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，首席會計官 Richard C. Malabre 於 6 月 9 日星期一出售了 15,000 股公司的股票，交易價格為每股平均$4.01，總交易額為$60,150.00。交易完成後，首席會計官直接持有 266,914 股公司股票，價值約為$1,070,325.14。此次交易代表其持股比例下降了 5.32%。該出售的披露信息可在此找到。在過去三個月中，內部人士共出售了 69,648 股公司股票，價值$258,841。內部人士持有公司股票的比例為 3.00%。</p>
<h2>對 Akebia Therapeutics 的對沖基金看法</h2>
<p>幾家大型投資者最近增加或減少了對該公司的持股。高盛集團在第一季度將其在 Akebia Therapeutics 的持股比例提高了 171.8%。高盛集團目前擁有 2,724,439 股生物製藥公司的股票，價值$5,231,000，此前在上個季度又購買了 1,722,245 股。AQR 資本管理公司在第一季度將其在 Akebia Therapeutics 的持股比例提高了 13.1%。AQR 資本管理公司目前擁有 176,961 股生物製藥公司的股票，價值$340,000，此前在上個季度又購買了 20,499 股。未來資產全球 ETF 控股有限公司在第一季度將其在 Akebia Therapeutics 的持股比例提高了 9.1%。未來資產全球 ETF 控股有限公司目前擁有 137,897 股生物製藥公司的股票，價值$265,000，此前在上個季度又購買了 11,517 股。最後，貝爾德金融集團在第一季度將其在 Akebia Therapeutics 的持股比例提高了 23.0%。貝爾德金融集團目前擁有 21,393 股生物製藥公司的股票，價值$41,000，此前在上個季度又購買了 4,000 股。機構投資者持有公司股票的比例為 33.92%。</p>
<h2>華爾街分析師的看法</h2>
<p>一些分析師對 AKBA 股票發表了看法。Leerink Partners 在 4 月 28 日星期一的報告中將 Akebia Therapeutics 的評級上調至 “強力買入”。HC Wainwright 在 6 月 4 日星期三的報告中開始覆蓋 Akebia Therapeutics。他們為該公司設定了 “買入” 評級和$8.00 的目標價。Wall Street Zen 在 5 月 3 日星期六的報告中將 Akebia Therapeutics 的評級從 “賣出” 上調至 “持有”。最後，Leerink Partners 在 4 月 28 日星期一的報告中對 Akebia Therapeutics 進行了覆蓋。他們為該公司設定了 “跑贏大盤” 的評級和$7.00 的目標價。一位股票研究分析師對該股票給予了持有評級，四位給予了買入評級，一位給予了強力買入評級。根據 MarketBeat.com 的數據，Akebia Therapeutics 目前的平均評級為 “買入”，平均目標價為$6.75。</p>
<p><strong>查看我們關於 AKBA 的最新報告</strong></p>
<h2>關於 Akebia Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Akebia Therapeutics, Inc.是一家生物製藥公司，專注於開發和商業化針對腎臟疾病患者的治療藥物。該公司的主要產品候選藥物是 Vafseo（vadadustat），這是一種口服缺氧誘導因子脯氨酸羥化酶抑制劑，目前正在進行 III 期臨牀試驗，旨在治療因慢性腎病（CKD）導致的貧血，適用於依賴透析和不依賴透析的患者。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票比 Akebia Therapeutics 更好</li>
<li>投資的股票類型有不同</li>
<li>保持冷靜：為什麼 Comfort Systems USA 是一個隱藏的 AI 贏家</li>
<li>什麼是財報？</li>
<li>Rocket Lab 下週報告：投資者需要知道的事項</li>
<li>股息支付比率計算器</li>
<li>蘋果股票：大額收益，小幅波動——是時候買入了嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Akebia Therapeutics 嗎？</h2>
<p>在考慮 Akebia Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Akebia Therapeutics 並不在名單上。</p>
<p>雖然 Akebia Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AKBA

<p>Akebia Therapeutics（納斯達克代碼：AKBA）將於 8 月 7 日發佈 2025 年第二季度財報，分析師預測每股收益為（$0.02），收入為 4760 萬美元。該公司最近報告了 2025 年第一季度每股收益為$0.03，超出預期。股價上漲 0.8%，至$3.72，市值為 9.7702 億美元。內部交易活動包括首席財務官 Erik Ostrowski 出售股份，機構投資者持有 33.92% 的股份。分析師對該股的評級不一，有些將其評級上調至 “強力買入”，並設定目標價高達$8.00</p>

<p>Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $47.60 million for the quarter.</p>
<div class="lb-trans"><p>Akebia Therapeutics（納斯達克股票代碼：AKBA - 獲取免費報告）預計將在 2025 年第二季度的季度財報發佈之前，於 8 月 7 日星期四市場開盤前發佈。分析師預計該公司將宣佈每股收益為（$0.02），季度收入為 4760 萬美元。</p>
</div><ul>
<li>Akebia Therapeutics Surges on FDA Approval for Anemia Treatment</li>
</ul>
<div class="lb-trans"><ul>
<li>Akebia Therapeutics 因 FDA 批准貧血治療而大幅上漲</li>
</ul>
</div><p>Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.06. The firm had revenue of $57.34 million during the quarter, compared to analyst estimates of $44.88 million. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Akebia Therapeutics（納斯達克股票代碼：AKBA - 獲取免費報告）最近一次發佈季度財報是在 5 月 8 日星期四。這家生物製藥公司報告該季度每股收益為$0.03，超出分析師一致預期的（$0.03）$0.06。該公司在該季度的收入為 5734 萬美元，而分析師預期為 4488 萬美元。分析師平均預計 Akebia Therapeutics 在當前財政年度的每股收益為$0，下一財政年度的每股收益也為$0。</p>
</div><p>Get <strong>Akebia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Akebia Therapeutics</strong> 的提醒：</p>
</div><h2>Akebia Therapeutics Trading Up 0.8%</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 股價上漲 0.8%</h2>
</div><p>Shares of NASDAQ AKBA traded up $0.03 during midday trading on Friday, reaching $3.72. The stock had a trading volume of 3,017,137 shares, compared to its average volume of 4,131,279. The firm has a market cap of $977.02 million, a price-to-earnings ratio of -17.71 and a beta of 0.88. Akebia Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.08. The company has a debt-to-equity ratio of 1.89, a quick ratio of 2.02 and a current ratio of 2.23. The company's 50 day moving average price is $3.61 and its 200 day moving average price is $2.64.</p>
<div class="lb-trans"><p>在週五的午盤交易中，納斯達克 AKBA 的股票上漲了$0.03，達到了$3.72。該股票的交易量為 3,017,137 股，而其平均交易量為 4,131,279 股。該公司的市值為 9.7702 億美元，市盈率為-17.71，貝塔值為 0.88。Akebia Therapeutics 的 12 個月低點為$1.07，12 個月高點為$4.08。該公司的債務與股本比率為 1.89，速動比率為 2.02，流動比率為 2.23。該公司的 50 日移動平均價格為$3.61，200 日移動平均價格為$2.64。</p>
</div><h2>Insider Transactions at Akebia Therapeutics</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 的內部交易</h2>
</div><p>In related news, CFO Erik Ostrowski sold 41,314 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $3.67, for a total value of $151,622.38. Following the transaction, the chief financial officer owned 503,586 shares of the company's stock, valued at approximately $1,848,160.62. This trade represents a 7.58% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CAO Richard C. Malabre sold 15,000 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $4.01, for a total transaction of $60,150.00. Following the completion of the transaction, the chief accounting officer directly owned 266,914 shares in the company, valued at approximately $1,070,325.14. The trade was a 5.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,648 shares of company stock worth $258,841 in the last three months. Insiders own 3.00% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Erik Ostrowski 於 6 月 30 日星期一出售了 41,314 股公司的股票，交易價格為每股平均$3.67，總價值為$151,622.38。交易後，首席財務官持有 503,586 股公司股票，價值約為$1,848,160.62。此次交易代表其持股比例下降了 7.58%。該出售在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，首席會計官 Richard C. Malabre 於 6 月 9 日星期一出售了 15,000 股公司的股票，交易價格為每股平均$4.01，總交易額為$60,150.00。交易完成後，首席會計官直接持有 266,914 股公司股票，價值約為$1,070,325.14。此次交易代表其持股比例下降了 5.32%。該出售的披露信息可在此找到。在過去三個月中，內部人士共出售了 69,648 股公司股票，價值$258,841。內部人士持有公司股票的比例為 3.00%。</p>
</div><h2>Hedge Funds Weigh In On Akebia Therapeutics</h2>
<div class="lb-trans"><h2>對 Akebia Therapeutics 的對沖基金看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its position in shares of Akebia Therapeutics by 171.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company's stock worth $5,231,000 after buying an additional 1,722,245 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Akebia Therapeutics by 13.1% during the 1st quarter. AQR Capital Management LLC now owns 176,961 shares of the biopharmaceutical company's stock worth $340,000 after buying an additional 20,499 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Akebia Therapeutics by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 137,897 shares of the biopharmaceutical company's stock worth $265,000 after buying an additional 11,517 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its position in shares of Akebia Therapeutics by 23.0% during the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 4,000 shares in the last quarter. Institutional investors own 33.92% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對該公司的持股。高盛集團在第一季度將其在 Akebia Therapeutics 的持股比例提高了 171.8%。高盛集團目前擁有 2,724,439 股生物製藥公司的股票，價值$5,231,000，此前在上個季度又購買了 1,722,245 股。AQR 資本管理公司在第一季度將其在 Akebia Therapeutics 的持股比例提高了 13.1%。AQR 資本管理公司目前擁有 176,961 股生物製藥公司的股票，價值$340,000，此前在上個季度又購買了 20,499 股。未來資產全球 ETF 控股有限公司在第一季度將其在 Akebia Therapeutics 的持股比例提高了 9.1%。未來資產全球 ETF 控股有限公司目前擁有 137,897 股生物製藥公司的股票，價值$265,000，此前在上個季度又購買了 11,517 股。最後，貝爾德金融集團在第一季度將其在 Akebia Therapeutics 的持股比例提高了 23.0%。貝爾德金融集團目前擁有 21,393 股生物製藥公司的股票，價值$41,000，此前在上個季度又購買了 4,000 股。機構投資者持有公司股票的比例為 33.92%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><p>A number of analysts have weighed in on AKBA shares. Leerink Partnrs upgraded Akebia Therapeutics to a &#34;strong-buy&#34; rating in a report on Monday, April 28th. HC Wainwright started coverage on Akebia Therapeutics in a report on Wednesday, June 4th. They set a &#34;buy&#34; rating and a $8.00 price target for the company. Wall Street Zen upgraded Akebia Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, May 3rd. Finally, Leerink Partners initiated coverage on Akebia Therapeutics in a report on Monday, April 28th. They set an &#34;outperform&#34; rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Akebia Therapeutics presently has an average rating of &#34;Buy&#34; and an average price target of $6.75.</p>
<div class="lb-trans"><p>一些分析師對 AKBA 股票發表了看法。Leerink Partners 在 4 月 28 日星期一的報告中將 Akebia Therapeutics 的評級上調至 “強力買入”。HC Wainwright 在 6 月 4 日星期三的報告中開始覆蓋 Akebia Therapeutics。他們為該公司設定了 “買入” 評級和$8.00 的目標價。Wall Street Zen 在 5 月 3 日星期六的報告中將 Akebia Therapeutics 的評級從 “賣出” 上調至 “持有”。最後，Leerink Partners 在 4 月 28 日星期一的報告中對 Akebia Therapeutics 進行了覆蓋。他們為該公司設定了 “跑贏大盤” 的評級和$7.00 的目標價。一位股票研究分析師對該股票給予了持有評級，四位給予了買入評級，一位給予了強力買入評級。根據 MarketBeat.com 的數據，Akebia Therapeutics 目前的平均評級為 “買入”，平均目標價為$6.75。</p>
</div><p><strong>Check Out Our Latest Report on AKBA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 AKBA 的最新報告</strong></p>
</div><h2>About Akebia Therapeutics</h2>
<div class="lb-trans"><h2>關於 Akebia Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.</p>
<div class="lb-trans"><p>Akebia Therapeutics, Inc.是一家生物製藥公司，專注於開發和商業化針對腎臟疾病患者的治療藥物。該公司的主要產品候選藥物是 Vafseo（vadadustat），這是一種口服缺氧誘導因子脯氨酸羥化酶抑制劑，目前正在進行 III 期臨牀試驗，旨在治療因慢性腎病（CKD）導致的貧血，適用於依賴透析和不依賴透析的患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Akebia Therapeutics</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Play It Cool: Why Comfort Systems USA Is a Hidden AI Winner</li>
<li>What Are Earnings Reports?</li>
<li>Rocket Lab Reports Next Week: Here’s What Investors Should Know</li>
<li>Dividend Payout Ratio Calculator</li>
<li>Apple Stock: Big Earnings, Small Move—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Akebia Therapeutics 更好</li>
<li>投資的股票類型有不同</li>
<li>保持冷靜：為什麼 Comfort Systems USA 是一個隱藏的 AI 贏家</li>
<li>什麼是財報？</li>
<li>Rocket Lab 下週報告：投資者需要知道的事項</li>
<li>股息支付比率計算器</li>
<li>蘋果股票：大額收益，小幅波動——是時候買入了嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=AKBA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Akebia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Akebia Therapeutics 嗎？</h2>
</div><p>Before you consider Akebia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Akebia Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Akebia Therapeutics 並不在名單上。</p>
</div><p>While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Akebia Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Akebia Therapeutics (AKBA) 將在週四公佈財報